13.35
+0.34(+2.61%)
Currency In USD
| Previous Close | 13.01 |
| Open | 12.9 |
| Day High | 13.42 |
| Day Low | 12.04 |
| 52-Week High | 28.09 |
| 52-Week Low | 11.1 |
| Volume | 715,606 |
| Average Volume | 501,747 |
| Market Cap | 726.45M |
| PE | -12.25 |
| EPS | -1.09 |
| Moving Average 50 Days | 13.49 |
| Moving Average 200 Days | 18.37 |
| Change | 0.34 |
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2025 9:01 PM GMT
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Maz
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
GlobeNewswire Inc.
Feb 11, 2025 9:01 PM GMT
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patie
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
GlobeNewswire Inc.
Jan 27, 2025 1:00 PM GMT
BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentatio